Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

I t’s hard to argue that the introduction of drugs like Ozempic has been anything short of revolutionary for people looking ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Since Ozempic hit the public consciousness as a weight-loss medication, one in eight Americans have tried it (or a version of it) to lose weight.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...